Pharmacology, Biochemistry and Behavior 1991: Vol 38 Index

7 Pages·1991·2.1 MB·English

VOLUME 38 1991
SUBJECT INDEX
AB mice, 471 Atropine, 747 Cerebrospinal fluid, 677
Acetylcholine, 115, 227, 501, 723, 731, Autoradiography, 621 CGS 10746B, 7
921 Aversive stimuli, 401, 795 Chicken, 247
Acetylcholinesterase, 93 Avoidance behavior, 191 Chlordiazepoxide, 13, 43, 299, 375, 433
Acetyltransferase, 813 p-Chloroamphetamine, 135
ACh release, 441 BC-264, 545 Choline, 723
Acomys cahirinus, 913 BC (3016), 401 Choline acetyltransferase, 861
Acoustic startle reflex, 769 BDZ receptor ligands, 13 Cholinergic, 227, 243, 501
Activity, 485 Behavior, 155, 539, 639, 817 Cholinergic muscarinic binding, 861
Acute dependence, 711 Behavior genetics, 893 Cholinergic supersensitivity, 105
Adenosine receptors, 1 Behavioral deficit, 441, 795 Cholinergic systems, 527
Adenosine uptake sites, 1 Behavioral economics, 715 Cholinesterase inhibitor, 549
Adenylate cyclase, 555 Behavioral pharmacology, 527 Chronic, 495
Adrenalectomy, 593 Behavioral teratology, 739 Chronic administration, 611
Adrenaline, 13, 299 Behavioral toxicology, 527 Chronic opioid agonists and antagonists,
a,-Adrenoceptor, 353 Benoxathian, 905 485
a-2-Adrenoceptor, 287 Benzodiazepine and fixed interval behavior, Chronic variable stress, 125
Affective disorders, 227, 695 823 Circadian rhythms, 253
Afterdischarge, 669 Benzodiazepine and spontaneous activity, Cigarette smoking, 333, 417
Aggression, 485, 587, 639 823 Circling training, 739
Aggressiveness, 471 Benzodiazepine inverse agonist, 763 Climbing, 463
Aging, 861 Benzodiazepine receptor, 99 Clonidine, 177
Alcohol-ethyl, 639 Benzodiazepines, 43, 781, 889 Clorgyline, 677
Alcohol intake, 881 Beta-funaltrexamine, 49 Cocaine, 267, 287, 353, 411, 467, 601,
Alpha-1 adrenergic receptors, 905 Bicuculline, 593 893, 897, 927
Alprenolol, 353 Bilateral transection, 931 Coffee, 333
Alzheimer’s disease, 141, 921 Binding, 231 Cognition, 169
Ambient temperature, 339 Blink rate, 869 Colchicine, 141
2-Amino-1,2-dihydronaphthalene (ADN), Blood-brain barrier, 155, 327 Cold challenge, 253
581 Blood ethanol concentration, 699 Cold exposure, 837
2-Aminoindan, 581 Blood pressure, 55, 601, 843 Cold-induced hypertension, 837
2-Aminotetralin (AT), 581 Body temperature, 29, 253 Cold stress, 813
Ambulatory activity, 781 Body weight, 495 Color discrimination, 55, 77
Amphetamine, 365, 375, 467, 927 Brain ethanol, 29 Compensatory tracking, 527
(+ )-Amphetamine, 581 Brain injury, 327 Computed tomography, 327
d-Amphetamine, 417, 633 Brain lesions, 869 Conditioned avoidance responses, 705
Amygdaloid kindling, 669 Brain serotonin, 775 Conditioned place preference, 7, 539
Analgesia, 155, 185, 401, 485, 561, 681, Brain-stimulation reward, 645 Conditioned position responding, 77
795, 853 Bright light, 227, 695 Conditioned suppression, 309
Analgesic, 21 2-Bromolisuride, 321 Conditioned taste aversion, 267, 375, 479
Analgesic agents, 909 BUBU, 155 Conditioning, 375
Angiotensin II, 913 Burying behavior, 63, 371, 807 Consolidation, 651
Angiotensin II-induced drinking, 837 Buspirone, 299, 611 Corticosterone, 13, 299
Animal model, 141, 889 Cross-dependence, 433
Animal model of depression, 191 CS7BL/6J mice, 177, 897 Cross-tolerance, 195, 427, 433
Anorexia, 459, 905 Caffeine, 333, 513 CSF, 677
Antagonism, 479 Calcium channel blocking agents, 55 CY 208-243, 259
Anterograde amnesia, 651 Canine narcolepsy, 1 Cyclo(His-Pro), 359, 365
Antidepressants, 621 Carbachol, 115 d-Cycloserine, 665
Antihypertensive agents—adverse side-ef- Carbamate, 527
fects, 55 Carbohydrate intake, 177 D,, 243
Antinociception, 287, 753 8-Carbolines, 519 D,, 243
Antiopiate, 273 5-Carboxamidotryptamine, 459 D, agonist, 147
Antiseizure efficacy, 665 Cardiotoxicity, 601 D1 receptor, 215, 259
Anxiety, 63, 99, 519, 651, 889 Cardiovascular, 333 D2 receptor, 215
Anxiety drugs, 769 Cardiovascular function, 843 DAGO, 155, 185
Anxiety reduction after ejaculation, 807 Cat, 287 Defeat, 485
Anxiolytics, 43 Catalepsy, 105, 673, 875 Delayed matching-to-sample, 77
Apomorphine, 309, 321, 463, 869, 917 Catecholamines, 345, 677 Delta and mu opioid receptors, 185
Appetitive conditioning, 109 Catecholamines, plasma, 843 Delta opioid agonist, 155
Approach behavior, 191 Cathinone, 7 Dependence, 433
Arousal, 333, 723 Caudate nuclei, 739 Depression, 315, 695
Arrhythmias, 601 CCK, 479 Desipramine, 621
Arterial blood pressure, 913 CCK antagonists, 207 Dexfenfluramine, 495, 775
ASU 1-7 eel calcitonin, 561 CCK-B receptors, 545 5,7-DHT, 807
Atipamezole, 287 Cellular tolerance, 29 Diazepam, 63, 389, 471, 65]
Atmospheric pressure, 639 Central nervous system, 147 Diet selection, 495
5,7-Dihydroxytryptamine, 447 Food adaptation, 85 Individual differences, 467
Discriminative stimulus, 407 Food intake, 223, 235, 359, 379, 417, 605, Indole-2-carboxyiic acid, 665
Displacement activities, 889 775 Inhalation, 699
Dispositional tolerance, 823 Footshock, 69 Insecticide, 235
Diurnal activity, 633 Foot shock-induced analgesia, 561 Insulin, 533
Dizocilpine, 673 Formalin test, 247 Intracerebroventricular, 185
DMCM, 13, 99 Forskolin, 753 Intracerebroventricular infusion, 379
DOCA-salt hypertension, 55 Frontal cortex, 93, 723 Intranigral infusion, 617
DOI, 353 FSL and FRL rats, 105 Intravenous administration, 155
Domestic fowl, 49, 587 Inverse agonist, 99, 519
Dominance, 587 GABA, 385, 659, 781, 801 Iodoaminoindan, 135
Dopamine, 7, 69, 147, 215, 505, 539, 705, GABA antagonist (RU 5135), 327 p-lodoamphetamine, 135
789, 869, 917 GABA, receptor, 235 3-Isobutyl-1-methylxanthine, 753
Dopamine antagonist, 321 GABA receptors, 829 Isoproterenol HCl, 913
Dopamine D-2 receptors, 131 Gap inhibition, 769
Dopamine receptors, 829 Gender differences, 253 Jaw-opening reflex, 287
Dopamine sensitivity, 105 Genetic obesity, 177
Dorsal raphe nucleus, 223 Ginkgo biloba, 109 Kainic acid, 689
Dose-effect, 141 Glutamate, 385 Kappa receptors, 401
DPDPE, 185 G-proteins, 1 Ketamine, 211, 869
Drinking, 253, 459, 913 Ketanserin, 605
Halazepam dependence, 561 Kindling, 163
Drug dependence, 389
Halazepam metabolism, 561
Drug discrimination, 7, 99, 211, 407, 519,
Halazepam pharmacokinetics, 561 L-365 ,260, 207
539, 581, 763
Haloperidol, 471, 633, 645, 739, 869, 875 Latent inhibition, 309
Drug effects, 77
Hamster, 711 Lateral ventricle, 705
Drug regimen, 927
HDL-C, 813 LD5o, 673
Drug seeking, 389
Head-twitch, 353 Learned helplessness, 93
DSP4, 807
Heart rate, 339, 843 Learned tolerance, 29
Early exposure, 575 Heat challenge, 253 Learning, 77, 231, 651
EDs,, 673 Hematocrit, 913 Learning and memory, 731
EEG, 293 Hematuria, 689 Lecithin:cholesterol, 813
Ejaculation, 371 Hexobarbital, 471 Lethality, 339, 673, 893
Eltoprazine (DU 28853), 447, 759 5-HIAA, 677 Lever press, 109
Endorphin, 909 Hippocampus, 93, 621, 705, 723, 801, 861 Levorphanol, 485
B-Endorphin, 795 Hot-plate, 185 LHRH, 705
Enkephalinase inhibitor, 21 HPLC-EC, 135 Licking, 463
Enkephalins, 155 5-HT,,, 691 Lindane, 235
Epilepsy, 163 5-HT,, 691 Lisuride, 321
Epileptic spiking, 327 5-HT agonists, 495 Lithium, 93, 375, 533
Escape deficit, 125 5-HT behavioral syndrome, 555 Locomotion, 155, 441
Eseroline, 747 5-HT receptors, 201 Locomotor activity, 265, 321, 385, 467,
Ethanol, 29, 293, 389, 427, 433, 639, 665, 5-HT,-like receptors, 459 723, 829, 875
699, 763 5-HT, receptors, 447 Locomotor/exploratory activity, 817
Ethanol initiation, 575 5-HT,, activity, 407 Locus coeruleus, 621
Ethanol reinforcement, 575 5-HT,, receptor, 353, 555 Long latency event-related potentials, 789
Ethopharmacology, 889 5-HT,, receptor agonist, 441 Long-term potentiation, 163
Ethyl-beta-carboline-3-carboxylate, 63 5-HT, receptor, 353
(+ )-a-Ethylphenethylamine, 581 5-HT, receptor antagonist, 169 Macronutrient selection, 177
Etorphine, 475 5-HTP, 201 Male and female rats, 795
Evaporative water loss, 339 Human, 417 Male sexual behavior, 201
Experience of defeat, 315 Hunger, 379 MAOI, 677
Exploration, 759 HVA, 677 Marble burying, 63
6-Hydroxydopamine, 215 Marmoset, 147, 169
Fat, 681 5-Hydroxytryptamine, 459 Maze, 759
Feed restriction, 587 5-Hydroxytryptamine (5-HT) or serotonin, McN-A-343, 115
Feeding, 379, 495 191 MDMA, 345, 539
Fenfluramine, 365 5-Hydroxytryptophan (5-HTP), 191 Meal-feeding, 177
Fentanyl, 475 Hyperalgesia, 247 Mechanisms of anesthesia, 639
FG 7142, 99, 519 Hyperbaric, 639 Mechanisms of intoxication, 639
Fimbria fornix, 931 Hyperbaric pressure, 219 Medetomidine, 287
Fixed ratio, 897 Hyperthermia, 339 Median raphe nucleus, 223
Fixed-ratio (FR) liquid-reinforced behavior, Hypertonic NaCl, 913 Memory, 77, 109, 141, 243, 651
699 Hypothalamus, 379 Memory search, 281
Fixed-ratio responding, 747 Hypothermia, 235, 339, 651 5-MeODMT, 201
Fixed-ratio schedule, 411 Metabolic rate, 339
Flumazenil, 13 ICI-154,129, 485 Metabolism, 345
2-(Fluorohydroxyphenyl)ethylamines, 131 ICS 205-930, 353, 605 Metaphit, 231
Fluoxetine, 495 Imipramine, 93, 125, 407, 621 Methohexital, 411
Flurazepam, 659 Impotence, 917 N-Methyl-D-aspartate, 673
Flurazepam, behavioral tolerance, 823 In vitro binding, 155, 621 5 ,6-Methylenedioxy-2-aminoindan (MDAI),
Flurazepam elimination half-life, 823 In vivo binding, 155, 621 581
Flurazepam pharmacokinetics, rat, 823 Incremental repeated acquisition, 77 Methylenedioxyamphetamines, 505
a-Methylepinine, 345 Nucleus accumbens, 829 Prolyl-leucyl-glycinamide, 273
N’-Methylnicotinium iodide, 843 Nucleus basalis magnocellularis, 731 Psychopharmacology, 375
Methysergide, 605 Psychosis, 927
Metoclopramide, 917 Obesity, 533 PTZ, 99
MHPG, 677 Object discrimination reversal, 169 Pyridostigmine, 549
Mice, 109, 485, 593, 639, 763, 817 ob/ob, 177
Microdialysis, 723 Obsessive-compulsive disorder, 63 Quantitative autoradiography, 447
Microtubule, 141 Occasional smokers, 281 Quinpirole, 309
Midazolam, 611 Offensive aggression, 447
MK-329, 207 8-OH-DPAT, 407 Radial-arm maze, 243
MK-801, 163, 211, 231, 665, 673 Ondansetron, 169 Rapid, 427
M. nemestrina, 677 Ontogeny of ingestion, 207 Rat, 7, 13, 37, 43, 93, 99, 201, 253, 267,
Monkeys, 77, 677, 869 Open field, 759 299, 309, 321, 427, 447, 467, 519, 533,
Morphinan, 401 Operant behavior, 77, 195 539, 545, 575, 617, 669, 685, 699, 731,
Morphine, 37, 49, 77, 185, 195, 247, 273, Operant conditioning, 141, 739 769, 893, 921, 927
673, 681, 711, 753, 817, 853 Operant performance, 549 Receptor binding, 691
Morphine dependence, 479 Opiate, 49, 247, 475, 673, 909 Receptor interactions, 829
Morris water maze, 651, 931 Opiates and drinking, 85 Receptor occupancy, 155
Mortality, 689 Opiates and feeding, 85 Receptors, 227, 501
Motivation, 77, 417 Opioid, 247, 673 Receptor turnover, 691
Motor activity, 339, 471, 633 Opioid antagonist, 185, 801 Recovery, 931
Motor behavior, 55, 259 Opioid peptides, 195, 775, 801 Reinforcement, 715
Motor execution, 781 Opioid receptors, 49, 155, 195, 853 Renin-angiotensin system, 837
Mouse, 259 Oral dyskinesia, 215 Renovascular hypertension, 55
MPTP, 147, 869 Oral movements, 617 Repeated ECS, 691
Mu, delta, kappa opioids, 485 Org2766, 931 Reserpine, 259
Multiple FR-TO schedule, 549 Organophosphate, 527 Resident-intruder, 447
Mu opioid agonist, 155 Osmotic minipump, 677 Residential laboratory, 417
Mu receptors, 401 Oxotremorine-M, 115 Restraint, 185
Muscarinic, 227, 243 Oxytocin, 273 Retention, 651
Muscarinic receptors, 695 Rhesus monkeys, 527
Pain, 49, 247
Muscarinic subtypes, 115 Ritanserin, 605
Mus musculus, 177 Palatability, 375 Ro 5-4864, 235
Pancreas, 909
Myoclonus, 235 Rol5-1788, 433
Paralytic effects, 475 Ro 15-4513, 763
N. accumbens, 705 Paraventricular nucleus, 905 Ro 20-1724, 753
Naloxone, 37, 43, 85, 247, 265, 371, 711, Parkinson’s disease, 147 Rodents, 147
747 Passive avoidance, 231, 931 Rolipram, 753
Naloxone hypophagia, 605 PCP, 231 Rotation, 659
Naltrexone, 485, 775, 853 PCPA, 253 Route of administration, 267, 601
Naltrindole, 49, 185 Penile erection, 131 RU 24969, 495
NAN-190, 407 Pentobarbital, 427
Narcotic antagonists, 247 Pentylenetetrazol, 471 Saccharin, 681
Narcotic drugs, 247 Peptides, 379 Saccharin concentrations, 37
Neurotoxicity, 505 Perforant path, 801 Salivation, 339
Neurokinin receptors, 223 Performance, 417 Satiety mechanism, 379
Neurokinins, 223 Peripheral benzodiazepine, 235 SCH 32615, 21
Neuroleptics, 645 Peripheral serotonergic mechanisms, 459 Schedule-controlled behavior, 611, 747
Neuromodulation, 365 Pertussis toxin, 561, 853 Schedule-induced polydipsia, 85
Neuropeptide Y, 379 Phencyclidine, 211 Scopolamine, 115, 243, 467, 723
Neuropeptide Y,_>7, 379 Phenoxybenzamine, 689 Scratching, 889
Neurotensin, 463, 569 Phenylpropanolamine, 905 Scuba divers, 219
Neurotoxicity, 135, 345, 505, 539 PHNO, 869 Seasonal affective disorder, 227
Neurotoxin, 689 Phosphoinositide turnover, 861 Second-order schedule, 411
NH.,-senktide, 881 Physostigmine, 115 Sedation, 651
Nicotine, 281, 333, 501, 875, 921 Picrotoxin, 235 Seizures, 235, 593
(+ )-Nicotine, 843 Pigeon, 407, 611 Self-administration, 411, 897
(—)-Nicotine, 843 Piloerection, 339 Self-stimulation, 645, 699
Nimodipine, 665 Pirenzepine, 115 Senktide, 223, 617
Nitrazepam, 265 Place conditioning, 513, 645 Sensitization, 467
NMDA, 385 Plasma renin activity, 837 Sensorimotor reactivity, 769
NMDA receptor, 665 Plasma B-endorphin, 219 Sensory contact model, 315
NMDA receptor antagonist, 163 Polyethylene glycol, 913 Septide, 617
Nociception, 49, 247, 287, 401 Position discrimination, 77 Serotonergic supersensitivity, 447
Nondeprived subjects, 223 Postsynaptic serotonin receptors, 191 Serotonin, 69, 135, 365, 459, 505, 539,
Nonhuman primates, 677, 889 Power spectra, 293 731, 789, 807
Nonhuman primates—baboons, 55 Precipitated withdrawal, 479 Serotonin agonist, 321, 459
Noradrenaline, 13, 299, 807 Preference test, 37 Serotonin analogs, 459
a-Noradrenergic, 177 Prefrontal cortex, 645 Serotonin antagonists, 459
Nor-binaltorphimine, 49 Preoptic area, 385 Serotonin depletion, 253
Norepinephrine, 69 Presynaptic receptor, 441 Serotonin receptors, 459
Novel object, 759 Principal Component Analysis (PCA), 817 Serotonin receptor subtypes, 605
Novelty, 467 Progressive ratio, 77 Sex, 533
Sexual behavior, 115, 273, 781 Subjective ratings, 281 Time perception, 77
Shock stress, 93 Submissive male, 315 Tobacco, 921
Shuttle-box, 125 Subsensitivity, 659 Tolerance, 265, 427, 433, 467, 485, 699,
Signalled punishment, 43 Substantia innominata, 385 843
SKF 38393, 215, 309 Substantia nigra, 617 Tooth pulp, 287
Skin temperature, 339 Substantia nigra pars reticulata, 659 Toxicity, 893
Sleep, 545 Sucrose, 681 Toxicokinetics, 235
Sleep-wake cycle, 293 Sudden death, 601 TRH, 669
Smoking, 715 Sulpiride, 533, 869 Tritiated probe, 155
Sniffing, 463 Supersensitivity, 853 Tryptophan, 587
Social attraction, 759 Substitutability, 715 Tyrosine-prolyl-leucyl-glycinamide, 273
Social behavior, 389, 417 Synaptosomes, 505
Social conflict, 485 U-50,488, 485
Social dominance, 389 Tachykinin analogues, 617 Ultrasonic motion detector, 633
Social isolation, 389 Tachykinins, 881 Upregulation, 853
Spatial learning, 931 Tail-flick, 185, 681
Verapamil, 55
Spiny mouse, 913 Tardive dyskinesia, 617
Vitamin A, 739
Spiperone, 215 Taste aversion, 513
Voltage-sensitive calcium channels, 665
Spontaneous alternation, 441 Taste reactivity test, 375
Spontaneous motor activity, 705 Telemetry, 339
Water deprivation, 913
Squirrel monkey, 411, 633 Temperature, 105
Water intake, 223, 379, 913
Stereotypy, 105, 463 Temperature regulation, 235
Wet dog shakes, 801
Stimulant, 339, 581 Temporal response differentiation, 77
Withdrawal, 485, 711
Stimulus properties of drugs, 99, 519, 539 Test battery, 77
Withdrawal signs, 433
Strain, 69 Test/treatment interaction, 817
Withdrawal symptoms, 281
Stress, 185, 299, 501 THBC, 519
Stretching and yawning, 131 Theory of depression, 191 Yawning, 917
Striatum, 93, 705, 723 Thiazide diuretics, 55 YM-14673, 669
Structure-activity relationships, 505 THIP, 659 Yohimbine, 63, 353
Subarachnoid catheterization, 685 Thyrotropin-releasing hormone, 359
Subjective effects, 417 Time-course, 747 Zimelidine, 63
AUTHOR INDEX
Abbott, B., 259 Bosy, T. Z., 593 Daniel, S. S., 763 Epstein, L. H., 715
Adams, J. U., 195 Bowers, B. J., 593 Danysz, W., 231 Eshel, G., 829
Afani, A., 705 Bowersox, S., 1 Darmani, N. A., 353 Ettenberg, A., 645
Agmo, A., 781 Brase, D. A., 219 Davies, B. T., 905
Ahlenius, S., 201 Breese, G. R., 621 Day, J., 723 Facchinetti, F., 795
Akarid, K., 37 Brewster, W. K., 345 De Boer, S. F., 13, 299 Falk, J. L., 823
Akil, H., 673 Brockwell, N. T., 513 DeBold, J. F., 639 Farabollini, F., 795
Alex, P. K., 699 Brown, G. C., 527 De Caro, G., 881 Fassberg, J. B., 621
Algeri, S., 931 Brusés, J. L., 739 de Kloet, E. R., 447 Feldon, J., 309
Ali, S. F., 861 Bulik, C. M., 715 Delay-Goyet, P., 155 Fernandez, H., 781
Alkana, R. L., 639 Burguera, J. L., 533 Del Vecchio, R. A., 211 Fernandez-Guasti, A., 371,
Alleva, E., 817 Burguera, M., 533 Dement, W., 1 807
Andrea, M. E., 125 de Saint Hilaire, Z., 545 Ferrari, C. M., 267
Cada, D. A., 115
Anisman, H., 69 Deutsch, S. I., 665 Ferrari, F., 131
Caggiula, A. R., 715
Aprison, M. H., 191 Dewey, W. L., 219 Fibiger, H. C., 723
Calcagnetti, D. J., 185
Azcurra, J. M., 739 Diaz-Veliz, G., 705 Fink, H., 321
Chan, A. W. K., 433
Dilsaver, S. C., 227, 501, Finn, D. A., 639
Chang, S.-C. J. L., 853
Baamonde, A., 155 695 Fischman, M. W., 417
Chaplin, R. I., 789
Babbini, M., 639 Dohanich, G. P., 115 Flemmer, D. D., 227
Chermat, R., 141
Bakshtanovskaya, I. V., 315 Dolan, S., 823 Foltin, R. W., 417
Chiarotti, F., 817
Bao, K., 763 Domeney, A. M., 147, 169 Fregly, M. J., 837
Chipkin, R. E., 21
Baptista, T., 533 Dong, L., 843 Frenk, H., 475
Chodera, A., 265
Barnes, M. I., 801 Douglass, L. W., 587 Fujimoto, K., 163
Christensen, A. V., 93
Barrett, J. E., 407 Dreher, J., 829
Claudi, F., 131
Bar-Ziv, J., 327 Drumheller, A., 463 Gacel, G., 155
Coffin, V. L., 21
Becker, A., 471 Drummer, H. L., 235 Gagne, M. A., 463
Coghill, R. C., 475
Becker, H. C., 763 Dulinski, J., 691 Garrick, N., 677
Cohen, Y., 775
Beczkowska, I. W., 605 Duncan, G. E., 621 Gennaro, M., 677
Cooley, R. K., 689
Behm, F. M., 333 Duvauchelle, C. L., 645 Geoffroy, M., 93
Copeland, R. L., Jr., 293,
Belleau, B., 401 George, F. R., 893, 897
699
Beninger, R. J., 513 Eastman, N. W., 219 Gerrard, P. A., 147, 169
Costall, B., 147, 169
Bensimon, G., 141 Eden, R. J., 147 Geter, B., 85
Cox, M., 677
Benvenga, M. J., 211 Ehlers, C. L., 789 Ghosh, T. K., 293, 699
Crocker, A. D., 105
Berninsone, P. M., 739 Eikelboom, R., 513 Gibbs, J., 207
Currie, P. J., 177
Biegen, M. T., 681 Ellison, G., 927 Gibson, B. M., 759
Czech, D. A., 913
Blick, D. W., 527 Elmer, G. I., 897 Giordano, J., 49
Bodnar, R. J., 605 Damsma, G., 723 Emerich, D. F., 875 Giroux, M. L., 695
Gispen, W. H., 931 Larsson, K., 201 Nanry, K., 861 Roques, B. P., 155, 545
Glennon, R. A., 353 Lau, C. E., 823 Naylor, R. J., 147, 169 Rose, J. E., 243, 333
Goldberg, S. R., 411, 897 Laviola, G., 817 Neill, D. B., 467 Rosenberg, H. C., 659
Gomez, R. A., 125 Lawrence, M. S., 869 Nichols, D. E., 135, 345, Rouch, C., 775
Gordon, C. J., 339 Lee, J. D., 549 581 Rubino, T., 569
Gori, E., 569 Lee, S.-F., 549 Nicholson, D., 753 Ruethrich, H.-L., 471
Gorzalka, B. B., 273 Leidenheimer, N. J., 99, 519 Nicolaidis, S., 545 Ruiz-Gayo, M., 155
Grecksch, G., 471 Lemaire, S., 401 Njung’e, K., 63
Guan, X.-M., 505 Leong, F. W., 433 Noda, Y., 441 Saldivar, A., 371, 807
Gunne, L., 617 Leshem, M., 475 Norman, A. B., 875 Samson, H. H., 575
Levin, E. D., 243 Novitzki, M. R., 665 Sanberg, P. R., 875
Hack, S., 281 Li, D., 685 Nowak, G., 691 Sasaki, H., 921
Hamdi, A., 215 Li, E. T. S., 495 Nowakowska, E., 265 Satinoff, E., 253
Handley, S. L., 63 Li, B., 252 Nyce, J. W., 379 Sawynok, J., 753
Hartgraves, S. L., 527 Liau, L. M., 555 Schanley, D. L., 433
Harvey, C. A., 147 Liminga, U., 617 Oberlender, R., 135, 581 Schechter, M. D., 7, 99,
Hawkins, M., 1 Lin, C.-H., 549 O’Callaghan, J. P., 339 519, 539
Heaton, J. P. W., 917 Lipton, J., 927 Ochi, Y., 441 Schino, G., 889
Heinsbroek, R. P. W., 795 Liu, W.-F., 549, 747 O’Connor, D. A., 267 Schipper, J., 447
Hernandez, L., 533 Loggi, G., 817 O’Connor, S., 1 Schneider, R., 471
Heyne, A., 389 Lorens, S. A., 223 Ojea, S. I., 739 Schnur, P., 711
Hienz, R. D., 55 Luck, K. A., 273 Oka, M., 441 Schou, J. S., 93
Hijzen, T. H., 769 Luo, S., 495 Olivier, B., 447 Schulze, G. E., 77
Hillman, D. E., 685 Lutfy, K., 853 Olson, K. G., 219 Sekizawa, K., 921
Hingtgen, J. N., 191 Ong, J., 829 Shah, G., 427
Holtzman, S. G., 185, 195, McConville, B. J., 875 Orosco, M., 775 Shanks, N., 69
633 McGee, M., 501 Ott, T., 321 Shea, M. M., 587
Hong, J.-S., 801 McKenna, D. J., 505 Overstreet, D. H., 105 Shechtman, O., 837
McMullan, D. M., 115
Hooks, M. S., 467 Owen, D. A. A., 147 Shih, J.-H., 549
McNamara, R. K., 651
Houdi, A. A., 843 Shimada, E., 441
Huang, J.-T., 909 McNaughton, N., 43 Paez, X., 379 Shofel, A., 309
Hudson, P. M., 801 Ma, C., 549 Pandey, U., 353 Shreve, P. E., 385
Hughes, R. A., 49, 247 Mackenzie-Taylor, D., 29 Papanek, P. E., 837 Shulgin, A. T., 505
Huntzinger, J. A., 665 Malatynska, E., 695 Parenti, M., 569 Sierra, V., 853
Mangum, K. A., 115 Paris, J. M., 223 Sijbesma, H., 447
Ikarashi, Y., 921 Markowska, A. L., 731 Park, W. K., 191 Simansky, K. J., 459
Iqbal, M., 909 Marks-Kaufman, R., 681 Parker, L. A., 375 Skelton, R. W., 651
Martin, B. R., 353 Parolaro, D., 569 Slangen, J. L., 13, 299, 769
Jackson, D. M., 829 Martin, W. R., 561 Patrini, G., 569 Sleight, A. J., 555
Jacquot, C., 775 Maruyama, Y., 921 Paul, I. A., 621 Sloan, J. W., 561
Jibiki, I., 163 Paule, M. G., 77 Smith, A. D., 467
Massi, M., 881
Johansson, P. E., 617 Peck, J. A., 227, 501 Smith, G. P., 207
Massi, P., 569
Johnson, M. P., 135, 345 Mastropaolo, J., 665 Penetrante, M. L., 433 Spear, D. J., 411
Jolicoeur, F. B., 401, 463 Perfumi, M., 881 Spruijt, B. M., 931
Matsuzaki, Y., 921
Jones, D. N. C., 169 Perkins, K. A., 715 Starr, B. S., 259
Matthies, H., 471
Jones, G. H., 467 Mayer, D. J., 475 Peroutka, S. J., 555 Starr, M. S., 259
Jones, L. F., 601 Megirian, D., 253 Perretta, G., 889 Steele, T. D., 345
Josephy, M., 931 Meguro, K., 921 Pertovaara, A., 287 St-Pierre, S., 463
Justice, J. B., Jr., 467 Pfaff, D. W., 359, 365 Stumpf, W. E., 621
Meisch, R. A., 897
Pitha, J., 555 Sufka, K. J., 49, 247
Menard, D., 401
Kalant, H., 427 Pitsikas, N., 931 Sutton, D., 909
Mench, J. A., 587
Kanarek, R. B., 681 Middaugh, L. D., 763 Polidori, C., 881 Syapin, P. J., 639
Katz, J. L., 411 Pompei, P. L., 881
Mignot, E., 1
Kauppila, T., 287 Pournaghash, S., 479 Tackett, R. L., 601
Miller, D. B., 339
Kaushik, M., 665 Miller, S., 527 Powell, K. R., 621 Takishima, T., 921
Kautz, M. A., 85 Pradhan, S. N., 293, 699 Tanco, S. A., 273
Mintz, M., 327
Kavaliers, M., 485 Pruitt, T., 561 Tandon, P., 861
Mitchell, C. L., 801
Kelly, M. E., 147 Tang, M., 823
Mitsushio, H., 223
Kelly, T. H., 417 Radulovacki, M., 1 Tapia, C., 705
Molina, V. A., 125
Kemble, E. D., 759 Ramsey, V. A., 659 Tarrasch, R., 327
Monaco, V., 889
Kemppainen, P., 287 Rawleigh, J. M., 759 Teskey, G. C., 485
Mora, S., 705
Kent, S., 253 Rech, R. H., 29 Tesserommatis, C., 813
Morgat, J.-L., 155
Kerenyi, S. Z., 527 Redmond, E., Jr., 869 Tietz, E. I., 659
Morgenstern, R., 321
Khanna, J. M., 427 Reeber, C., 837 Tilson, H. A., 861
Mos, J., 447
Kimball, C. D., 909 Reid, A., 753 Tolliver, G. A., 575
Mundy, W. R., 861
Koryakina, L. A., 315 Reite, M., 677 Tomkowiak, J. M., 253
Muntaner, C., 411
Kostrzewa, R. M., 215 Rijnders, H. J., 769 Touzani, K., 37
Murphy, M. R., 527
Kow, L.-M., 359, 365 Riley, A. L., 85, 267, 479 Tripathi, H. L., 219
Murua, V. S., 125
Kubota, T., 163 Rios, C., 807 Tripp, G., 43
Murzi, E., 533
Kudryavtseva, N. N., 315 Rivest, R., 401, 463 Troisi, A., 889
Myers, R. D., 379
Kusanovic, R., 705 Robert, J. J., 775 Trujillo, K. A., 673
Myslobodsky, M. S., 327
Rodefer, J., 715 Tsopanakis, C., 813
Langan, M. C., 433 Nader, M. A., 611 Rogers, B. C., 861 Turkkan, J. S., 55
Turndorf, H., 685 Van Loon, G. R., 843 West, R., 281 Yamamoto, M., 669, 921
Tvede, K., 93 Varrin, S. J., 917 Wetherington, C. L., 85 Yanai, M., 921
Tyers, M. B., 169 Velley, L., 37 White, E. S., 681 Yatsugi, S., 669
Tyrka, A., 207 Wilkins, J., 927 Yim, G. K. W., 345
Wala, E. P., 561 Wilson, L. M., 177 Yoburn, B. C., 853
Uretsky, N. J., 385 Wall, T. L., 789 Wing, A. V., 211 Young, C. W., 633
Wang, B. C., 685 Winter, E., 109
van Aken, H., 447 Watkinson, W. P., 339 Wolffgramm, J., 389 Zacharko, R. M., 69
van Bergen, P., 837 Wehner, J. M., 593 Wong, L. S., 829 Zalcman, S., 69
Van De Poll, N. E., 795 Weiner, I., 309 Woolley, D. E., 235 Zanol, M. D., 875
Van Der Gugten, J., 13, 299 Weiner, J., 427 Wright, A., 147 Zeigler, S., 927
Vanderwolf, C. H., 689 Wellman, P. J., 905 Zhang, L., 407
Vander Zanden, J. M., 913 Wenk, G. L., 731 Yamaguchi, N., 163